Analyst Price Target is $31.67
▲ +174.88% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for 2seventy bio in the last 3 months. The average price target is $31.67, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 174.88% upside from the last price of $11.52.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in 2seventy bio.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.